Heparin Market Size
Market Overview
Heparin, commonly known as unfractionated heparin (UFH), is a naturally occurring glycosaminoglycan. It is used in medicine as an anticoagulant (blood thinner). It is very beneficial in the treatment of heart attacks and angina pectoris. It's injected either into a vein or under the skin. Acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during heart surgery, are all treated with it. It can also be used to provide major orthopedic surgeries like hip and knee replacements. The COVID-19 pandemic has caused chaos on health-care workflows all around the world. A huge number of individuals are suffering from coronavirus, which is associated to respiratory disorders, during the COVID-19 pandemic. As a result, the demand for heparin has risen, as it aids in the management of pulmonary inflation and the thinning of the blood of people at risk of a blood clot.
Heparin Market: Key Players
- Baxter International Inc.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
- B. Braun Holding GmbH & Co. KG
- Dr. Reddy’s Laboratories Ltd.
- Fresenius SE & Co KGaA
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- Leo Pharma A/S
- Pfizer Inc.
- Sanofi S.A
- Teva Pharmaceuticals
- Viatris Inc.
Growth Factor
Rising Incidence of Chronic Disorders to Incite market growth
The rising global prevalence of cardiovascular disorders, such as heart attacks and strokes, will provide market possibilities. According to the American Heart Association's (AHA) Heart Disease and Stroke Statistics, atrial fibrillation affected 5.3 million Americans in 2019. The rising patient demand for heparin might have a significant influence on the market.
Segmentation
- By Product
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMWH)
- By Application
- Venous Thromboembolism
- Coronary Artery Disease
- Atrial Fibrillation
- Others
- By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Heparin market Dynamics
- Heparin market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Recent News Related to Market
-
In December 2020, Valeo Pharma Inc. gained approval from Health Canada for its low molecular weight heparin 'Redesca and Redesca HP'.
-
In May 2020, The University of Manitoba launched a research research to see if heparin, a blood-thinning medicine, can be used to treat COVID-19 patients. The clinical experiment took place in 35 different locations across Canada, the United States, Mexico, and Brazil.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
- COVID-19 pre and post business impact analysis
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- What is the Heparin market growth?
- Which segment accounted for the largest Heparin market share?
- Who are the key players in the Heparin market?
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Frequently Asked Questions (FAQ):
Heparin market refers to global production and consumption of heparin and its derivatives (such as unfractionated heparin and low-molecular-weight heparin) used primarily as anticoagulants in cardiovascular, surgical and dialysis settings.
Recent estimates indicate global market size of about USD 9–10 billion in the mid-2020s, with projections reaching around USD 13–14 billion by the early 2030s, reflecting a moderate compound annual growth rate (CAGR) of roughly 4–7%
Growth is driven by rising incidence of cardiovascular and thrombo-embolic disorders, increasing surgical and dialysis procedures, growth of geriatric populations, and expansion of anticoagulant use in newer indications such as oncology and medical devices.
Challenges include raw-material sourcing issues (most heparin is derived from porcine gut), regulatory scrutiny and safety concerns (such as past contamination events), competition from alternative anticoagulants, and pricing pressures in developed markets.
Key segments include by product type (unfractionated vs low-molecular-weight heparin), by source material (porcine vs bovine vs synthetic), by route of administration (intravenous, subcutaneous), by application (deep vein thrombosis, atrial fibrillation, dialysis), and by region.
Select License Type
.png){kind=icon}
